Beyond the boundaries of LC-MS proteomics with next- generation all-in-one nano-, capillary- and micro-flow LC

Nano-, capillary- and micro-flow liquid chromatography (LC) with high-performing low-flow columns and High-Resolution Accurate-Mass (HRAM) Orbitrap MS or sensitive triple-quadrupole (TSQ) MS is enabling scientist to extend the biological knowledge and push science forward. Next-generation UHPLC technology and separation columns bring required robustness, innovation, and intelligence for discovery, validation, and translational LC-MS studies. All-in-one nano-, capillary-, and micro-flow LC for high-sensitivity LC-MS workflows is accelerating productivity and enabling LC-MS users to get high-quality results every time.

Learning Objectives:

• How next-generation low-flow LC technology and columns enable deeper, faster, and quantitative proteome profiling
• How to increase nanoLC-MS productivity, optimize sensitivity and achieve record results for the single-shot analysis of proteomics samples
• How to analyze thousands of proteomics samples without compromising results quality

Presenter: Bernhard Kuster (Professor and Chair of Proteomics, Technical University, Munich, Germany)

Bernhard Kuster is a chemist by training and obtained is PhD in Biochemistry from the University of Oxford. He did a PostDoc funded by an EMBO long-term fellowship at the EMBL in Heidelberg and the University of Southern Denmark in Odense. After seven years as Vice President Analytical Sciences and Informatics at the biotech firm Cellzome (now GSK), he became Full Professor of Proteomics at the Technical University of Munich (TUM) in 2007. He currently is also the Director of the Bavarian Biomolecular Mass Spectrometry Center, a Carl von Linde Senior Fellow of the TUM Institute for Advanced Study and Vice Dean of Information Management of the School of Life Sciences at TUM.

Bernhard’s research focuses on three main topics: First, mapping proteomes to identify which genes exist as proteins, where they are expressed, in what quantities, how they are post-translationally modified, what their lifetimes are and any many further properties of interest for understanding biological systems. Second, investigating how therapeutic cancer drugs work at the molecular level to understand their often multiple modes of action and he has received an ERC Advanced Grant in 2019 aiming to integrate proteomics into precision medicine. Third, building proteome tools particularly in the areas of sample preparation, LC-MS/MS and informatics to improve and broaded the technological basis of proteomic technology.

Bernhard is a member of the German National Academy of Sciences Leopoldina and has received a number of awards, notably the Discovery in Proteomic Sciences Award of the Human Proteome Organisation (HUPO) for mapping out a draft of the human proteome. He has published more than 200 papers on proteomics and bioinformatics and has co-founded two start-up companies that operate in the area of proteomics and artificial intelligence.

Presenter: David H Perlman (Senior Principal Scientist, Director of Ultrasensitive Proteomics, Merck Exploratory Sciences Center, Cambridge)

David H. Perlman has spent a quarter-century at the interface between Biomedicine and Mass Spectrometry. He is a Physicist and Biologist by training, having his Ph.D. in Virology from Boston University School of Medicine and forging expertise in Proteomics and Mass Spectrometry as a Post-doctoral Fellow specializing in post-translational modification at the Center for Biomedical Mass Spectrometry at Boston Medical Center under Cathy Costello’s leadership. For the next half decade, he served as Director of the Collaborative Proteomics Center that he established at Princeton University, where he orchestrated a wide variety of cutting-edge research endeavors in Biology, Biochemistry, and Biomedicine. He left to cofound the chemoproteomics biopharma startup, Crescenta Biosciences, where he served as VP of Target Discovery, before being drawn to work together with Prof. Nikolai Slavov at Northeastern University to build the foundations of Single-Cell Proteomics. In 2018, he was recruited to the Merck Exploratory Sciences Center Cambridge, where he currently leads the internal Proteomics program and develops ultrasensitive chemoproteomics and single-cell proteomics methods to investigate critical processes in disease biology and therapeutic response. He is the co-author of more than 50 peer-reviewed articles, hundreds of presentations at international conferences, and pending patents.

Presenter: Karl Mechtler (Head of Protein Chemistry Facility bei Research Institute of Molecular Pathology (IMP), Vienna Biocore Facilities, Austria)

Karl Mechtler established one of the first Proteomics Core Facility in Austria in 2000, which is embedded in the Campus Vienna Biocenter and available to scientists from the Research Institute of Molecular Pathology (IMP), the Institute of Molecular Biotechnology (IMBA), and the Gregor Mendel Institute (GMI) today. He is developing methods for the analysis of protein post-translational modifications (phosphorylated arginine, glycoproteomics), algorithms for qualitative and quantitative MS data analysis that are increasingly used by proteomics labs worldwide. He is the co-author of more than 180 publications including contributions in Nature, Cell, and Science. The main research areas cover Proteomics, Mass Spectrometry, and Bioinformatics with specialization PTMs, cross-linking MS, single-cell proteomics, protein identification and quantification, etc.

Presenter: Alexander Boychenko (Product Marketing Manager, Thermo Fisher Scientific)

Alexander Boychenko is a Product Marketing Manager in the Chromatography and Mass Spectrometry group at Thermo Fisher Scientific, Inc. focused on bringing innovative applications and life science technologies to market. He holds a Ph.D. in Analytical Chemistry, and before joining the company worked as a post-doctoral researcher at the University of Groningen, The Netherlands, where he developed LC-MS techniques for discovery and validation of protein biomarkers in cervical cancer diagnostics. With a strong scientific background in chromatography, mass spectrometry, physical chemistry, chemometrics, and bioinformatics Alexander is a subject matter expert in LC-MS analysis and theory, new separation technologies, multidimensional separations, LC-MS data analysis and data interpretation in proteomics, biomarker discovery and validation. He utilizes his passion for translating scientists’ technology and application requirements into novel nano-, capillary-, and micro-flow LC-MS workflows and LC products seamlessly hyphenated with mass-spectrometry instruments.